Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,210 result(s) found for: Blood Test. Displaying page 410 of 711.
    «« First « Previous 406  407  408  409  410  411  412  413  414  Next» Last»»
    EudraCT Number: 2016-003291-47 Sponsor Protocol Number: RHMCAN1235 Start Date*: 2017-01-25
    Sponsor Name:University Hospital Southampton NHS Trust
    Full Title: A phase Ib/IIa clinical trial to combine the CSF1 receptor inhibitor pexidartinib with the androgen receptor antagonist enzalutamide in metastatic castration resistant prostate cancer
    Medical condition: Metastatic Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001346-34 Sponsor Protocol Number: IMM-101-015 Start Date*: 2018-07-27
    Sponsor Name:Immodulon Therapeutics Ltd
    Full Title: A Study of the Safety and Efficacy of IMM-101 in Combination with Checkpoint Inhibitor Therapy in Patients with Advanced Melanoma
    Medical condition: Unresectable, Stage III or Stage IV metastatic melanoma who are either previously untreated (cohort A), or whose disease has progressed during PD-1 blockade (cohort B).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028980 Neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-007083-28 Sponsor Protocol Number: HOVON85NHL Start Date*: 2008-06-18
    Sponsor Name:HOVON foundation
    Full Title: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partia...
    Medical condition: Aggressive B-cell NHL
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-002216-40 Sponsor Protocol Number: CML1516 Start Date*: 2016-10-04
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: BOSUTINIB EFFICACY SAFETY TOLERABILITY (BEST) STUDY IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS FAILING FRONT-LINE TREATMENT WITH OTHER TYROSINE KINASE INHIBITORS
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001748-24 Sponsor Protocol Number: ImmCoVA Start Date*: 2020-05-15
    Sponsor Name:Karolinska University Hospital
    Full Title: A multi-center, randomized, open-label study in patients with COVID-19 and respiratory distress not requiring mechanical ventilation, to compare standard-of-care with anakinra and tocilizumab treat...
    Medical condition: COVID-19 infection in patients with respiratory distress.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003559-39 Sponsor Protocol Number: 2011PP02 Start Date*: 2013-10-01
    Sponsor Name:The University of Dundee [...]
    1. The University of Dundee
    2. NHS TAYSIDE
    Full Title: Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease (ALL-HEART)
    Medical condition: Ischaemic Heart Disease (IHD), angina or myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004849 10023024 Ischaemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-005836-31 Sponsor Protocol Number: DHCL2021 Start Date*: 2021-04-07
    Sponsor Name:Steno Diabetes Center Copenhagen
    Full Title: Dual-Hormone Closed-Loop Glucose Control in Adolescents with Type 1 Diabetes
    Medical condition: Patients with type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10012608 Diabetes mellitus insulin-dependent LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001710-28 Sponsor Protocol Number: INCB59872-101 Start Date*: 2018-01-23
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
    Medical condition: Potential subjects include those with advanced or metastatic malignancies who are ineligible for all therapeutic options that are standard of care or known to confer clinical benefit, or who refuse...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000717-24 Sponsor Protocol Number: 230390 Start Date*: 2017-08-24
    Sponsor Name:Aarhus University Hospital
    Full Title: Concentration of piperacillin in plasma and subcutis in patients on crrt treatment
    Medical condition: infections reloated to CRRT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000019640 10021804 Infection bacterial LLT
    20.0 100000015677 10021863 Infection respiratory LLT
    20.0 100000165071 10021867 Infection systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000966-12 Sponsor Protocol Number: EL-004 Start Date*: 2019-11-18
    Sponsor Name:Eloxx Pharmaceuticals Inc
    Full Title: A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients with Cystic Fibrosis...
    Medical condition: Cystic fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005752-38 Sponsor Protocol Number: CBAF312ADE03 Start Date*: 2021-03-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants with secondary progressive multiple sclerosis treated with Mayzent (siponimod) (AMA-VACC)
    Medical condition: secondary progressive multiple sclerosis (SPMS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001680-69 Sponsor Protocol Number: B01-04 Start Date*: 2021-05-17
    Sponsor Name:Athersys, Inc.
    Full Title: MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study (MASTERS-2)
    Medical condition: Acute ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006691-17 Sponsor Protocol Number: D5180C00024 Start Date*: 2022-07-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 40-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Depend...
    Medical condition: Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003527-11 Sponsor Protocol Number: ING200336 Start Date*: 2014-05-13
    Sponsor Name:ViiV Healthcare, S.L.
    Full Title: ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women.
    Medical condition: HIV-infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10020160 HIV disease LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001200-20 Sponsor Protocol Number: CSET 1287 Start Date*: 2007-06-01
    Sponsor Name:Institut Gustave Roussy
    Full Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer
    Medical condition: adenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001127-40 Sponsor Protocol Number: GO40554 Start Date*: 2019-05-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVI...
    Medical condition: B-cell non-Hodgkin lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-017346-32 Sponsor Protocol Number: 201228 Start Date*: 2010-03-15
    Sponsor Name:Fondazione Telethon
    Full Title: A PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME
    Medical condition: Wiskott-Aldrich Syndrom
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10061598 Immunodeficiency PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001392-32 Sponsor Protocol Number: SC-VLU-001 Start Date*: 2021-11-10
    Sponsor Name:SolasCure Ltd
    Full Title: An adaptive open label, multiple ascending dose study of the safety, tolerability and bio-effect of Aurase for wound debridement in patients with venous leg ulcers and diabetic foot ulcers (CLEANVL...
    Medical condition: Venous Leg Ulcer Diabetic Foot Ulcer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10066677 Chronic leg ulcer LLT
    24.0 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-004050-16 Sponsor Protocol Number: HEAT-AML Start Date*: 2019-08-01
    Sponsor Name:University Hospital Karolinska
    Full Title: HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multicenter study to assess the tolerability and efficacy of the addition of hydroxyurea to standard a...
    Medical condition: Newly diagnosed acute myeloid leukaemia (AML) in patients ≥ 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005446-11 Sponsor Protocol Number: FFM-CIK-CellStudy01 Start Date*: 2015-05-28
    Sponsor Name:Goethe-University Frankfurt
    Full Title: A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplasti...
    Medical condition: relapsing acute leukemia, relapsing myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000835 Acute leukemia LLT
    17.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 406  407  408  409  410  411  412  413  414  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 10:09:54 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA